No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MRK240705P127000
- 0.32
- -3.28-91.11%
15min DelayClose Jul 1 16:00 ET
0.88High0.30Low
0.80Open3.60Pre Close265 Volume1.17K Open Interest127.00Strike Price11.84KTurnover14.90%IV0.95%PremiumJul 5, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.32Extrinsic Value100Contract SizeAmericanOptions Type-0.3147Delta0.1737Gamma304.52Leverage Ratio-0.0855Theta-0.0042Rho-95.84Eff Leverage0.0488Vega
Intraday
- 5D
- Daily
News
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Deutsche Numis Downgrades Merck & Co(MRK.US) to Hold Rating, Raises Target Price to $140
Express News | Merck Shares Are Trading Higher After the Company and Orion Announced the Mutual Exercise of an Option to Convert the Companies' Ongoing Co-development and Co-commercialization Agreement for Opevesostat Into an Exclusive Global License for Merck
Market Whales and Their Recent Bets on MRK Options
Express News | Merck Shares up 3.8%
Orion Upgrades FY24 Outlook After Modifying Agreement With Merck & Co
Comments
$Merck & Co(MRK.US$I think it’s just a temp pullback, it just broke the double-bottom line as well as the recent resistence simetanously. The pullback volume is also lower. Expecting new ATH.
4
$Merck & Co(MRK.US$ on the prowl for acquisitions up to $15 billion.
$Merck & Co(MRK.US$ already has an active partnership with $Janux Therapeutics(JANX.US$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US$ in which $Merck & Co(MRK.US$ already has a seat at the table.
$Merck & Co(MRK.US$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
$Merck & Co(MRK.US$ already has an active partnership with $Janux Therapeutics(JANX.US$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US$ in which $Merck & Co(MRK.US$ already has a seat at the table.
$Merck & Co(MRK.US$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
+1
9
🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
8
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Harmony Biosciences(HRMY.US$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US$ : KRESLADI (Marnetegragene autotemcel)
$Harmony Biosciences(HRMY.US$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US$ : KRESLADI (Marnetegragene autotemcel)
14
$Merck & Co(MRK.US$ 🎉
FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine)
⇨ for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults 🫁
» CAPVAXIVE (V116) protects against most strains causing illness in adults over 50. 🛡️
» Effective in people who've never had a pneumococcal vaccine or already have one as demonstrated in Ph3 trials.
FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine)
⇨ for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults 🫁
» CAPVAXIVE (V116) protects against most strains causing illness in adults over 50. 🛡️
» Effective in people who've never had a pneumococcal vaccine or already have one as demonstrated in Ph3 trials.
10
1
Read more